{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:43:23Z","timestamp":1794048203400,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s40265-020-01405-w","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T06:17:07Z","timestamp":1600409827000},"page":"1731-1737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Tafasitamab: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"1405_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-016-0875-x","author":"W Jurczak","year":"2016","unstructured":"Jurczak W, Bryk AH, Mensah P, et al. Single-agent MOR208 salvage and maintenance therapy in a patient with refractory\/relapsing diffuse large B-cell lymphoma: a case report. J Med Case Rep. 2016. https:\/\/doi.org\/10.1186\/s13256-016-0875-x.","journal-title":"J Med Case Rep"},{"issue":"7","key":"1405_CR2","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonzalez Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978\u201388.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1405_CR3","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00277-015-2467-z","volume":"94","author":"F Hitz","year":"2015","unstructured":"Hitz F, Connors JM, Gascoyne RD, et al. Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment. Ann Hematol. 2015;94(11):1839\u201343.","journal-title":"Ann Hematol"},{"issue":"6","key":"1405_CR4","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1182\/blood-2009-06-229039","volume":"115","author":"FT Awan","year":"2010","unstructured":"Awan FT, Lapalombella R, Trotta R, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood. 2010;115(6):1204\u201313.","journal-title":"Blood"},{"key":"1405_CR5","unstructured":"MorphoSys. FDA approves Monjuvi\u00ae (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [media release]. 31 July 2020. https:\/\/www.morphosys.com\/."},{"key":"1405_CR6","unstructured":"Morphosys US Inc. MONJUVI\u00ae (tafasitamab-cxix) for injection, for intravenous use: US prescribing information. 2020. https:\/\/www.fda.gov\/. Accessed 13 Aug 2020."},{"key":"1405_CR7","unstructured":"US FDA. FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma [media release]. 3 Aug 2020. https:\/\/www.fda.gov\/."},{"key":"1405_CR8","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): B-cell lymphomas. 2020. https:\/\/www.nccn.org. Accessed 20 Aug 2020."},{"key":"1405_CR9","unstructured":"Incyte Corporation and MorphoSys. Incyte and MorphoSys announce the validation of the European Marketing Authorization Application for tafasitamab [media release]. 20 May 2020. https:\/\/www.incyte.com."},{"key":"1405_CR10","unstructured":"MorphoSys. MorphoSys's MOR208 program to receive Orphan Drug Designation from FDA and EMA for the treatment of CLL\/SLL [media release]. 20 May 2014. https:\/\/www.morphosys.com."},{"key":"1405_CR11","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation: humanised Fc engineered monoclonal antibody against CD19 for the treatment of chronic lymphocytic leukaemia\/small lymphocytic lymphoma [media release]. 11 Jul 2014. https:\/\/www.ema.europa.eu\/."},{"key":"1405_CR12","unstructured":"MorphoSys and Xencor. MorphoSys and Xencor sign license and collaboration agreement for clinical antibody program [media release]. 27 June 2010. https:\/\/www.xencor.com."},{"key":"1405_CR13","unstructured":"MorphoSys. MorphoSys and Incyte sign global collaboration and license agreement for tafasitamab [media release]. 13 Jan 2020. https:\/\/www.morphosys.com."},{"issue":"19","key":"1405_CR14","doi-asserted-by":"publisher","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","volume":"68","author":"HM Horton","year":"2008","unstructured":"Horton HM, Bernett MJ, Pong E, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008;68(19):8049\u201357.","journal-title":"Cancer Res"},{"key":"1405_CR15","doi-asserted-by":"crossref","unstructured":"Horvei P, Sakemura R, Cox MJ, et al. Targeting of CD19 by tafasitamab does not impair CD19 directed chimeric antigen receptor T cell activity in vitro [abstract no. 2859]. Blood. 2019;134(Suppl 1).","DOI":"10.1182\/blood-2019-130506"},{"issue":"24","key":"1405_CR16","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1182\/blood-2014-08-593269","volume":"124","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Awan F, Flinn IW, et al. A phase I trial of the Fc engineered CD19 antibody XmAb(R)5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed chronic lymphocytic leukemia. Blood. 2014;124(24):3553\u201360.","journal-title":"Blood."},{"issue":"5","key":"1405_CR17","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/annonc\/mdy092","volume":"29","author":"S Makita","year":"2018","unstructured":"Makita S, Tobinai K. Antibody therapy targeting CD19 for B-cell non-Hodgkin's lymphoma. Ann Oncol. 2018;29(5):1086\u20139.","journal-title":"Ann Oncol"},{"key":"1405_CR18","doi-asserted-by":"crossref","unstructured":"Boxhammer R, Striebel F, Baumgartner R, et al. Expression of CD19 antigen on chronic lymphocytic leukemia cells after tafasitamab (anti-CD19) treatment: phase I trial data [abstract no. 5061]. Blood. 2019;134(Suppl 1).","DOI":"10.1182\/blood-2019-128613"},{"issue":"5","key":"1405_CR19","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","volume":"29","author":"W Jurczak","year":"2018","unstructured":"Jurczak W, Zinzani PL, Gaidano G, et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Ann Oncol. 2018;29(5):1266\u201372.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"1405_CR20","first-page":"560","volume":"4","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonzalez-Barca E, et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma [abstract no. EP1201]. HemaSphere. 2020;4(Suppl 1):560\u20131.","journal-title":"HemaSphere."},{"issue":"Suppl 1","key":"1405_CR21","first-page":"78","volume":"4","author":"PL Zinzani","year":"2020","unstructured":"Zinzani PL, Rodgers T, Marino D, et al. RE-MIND study: comparison of tafasitamab + lenalidomide (L-MIND) vs lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed\/refractory diffuse large B-cell lymphoma [abstract no. S238]. HemaSphere. 2020;4(Suppl 1):78\u20139.","journal-title":"HemaSphere."},{"key":"1405_CR22","doi-asserted-by":"crossref","unstructured":"Staber PB, Jurczak W, Brugger W, et al. Primary analysis of anti-CD19 tafasitamab (MOR208) treatment in combination with idelalisib or venetoclax in R\/R CLL patients who failed prior BTK inhibitor therapy (COSMOS trial) [abstract no. 1754]. Blood. 2019;134(Suppl 1).","DOI":"10.1182\/blood-2019-128388"},{"key":"1405_CR23","doi-asserted-by":"crossref","unstructured":"Staber PB, Chanan-Khan AA, Munir T, et al. Two-cohort phase II study in R\/R CLL (COSMOS): first preliminary safety and efficacy results of anti-CD19 MOR208 treatment in combination with venetoclax in patients who discontinued prior BTK inhibitor therapy [abstract no. 4433]. Blood. 2018;132(Suppl 1).","DOI":"10.1182\/blood-2018-99-114489"},{"key":"1405_CR24","doi-asserted-by":"crossref","unstructured":"Jurczak W, Zinzani PL, Hess G, et al. A phase IIa, open-label, multicenter study of single-agent tafasitamab (MOR208), an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma: long-term follow-up, final analysis [abstract no. 4078 plus poster]. Blood. 2019;134(Suppl 1).","DOI":"10.1182\/blood-2019-124297"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01405-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01405-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01405-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T21:00:58Z","timestamp":1631912458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01405-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":24,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1405"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01405-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]},"assertion":[{"value":"18 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sheridan Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}